LACK OF ACTIVITIES OF AMIKACIN AND SULFAMETHOXAZOLE AGAINST MYCOBACTERIUM-AVIUM-INTRACELLULARE
Publication in refereed journal


Full Text

Times Cited
Web of Science0WOS source URL (as at 31/03/2020) Click here for the latest count

Other information
AbstractTwenty clinical isolates of Mycobacterium avium-intracellulare were tested with amikacin and sulphamethoxazole for in-vitro susceptibilities. The MICs and MBCs of the former drug ranged from 8 to >64 mg/L (median MIC: 64 mg/L, median MBC: >64 mg/L). The MICs and MBCs of the latter drug were found to be >256 mg/L. Each of eight patients with invasive pulmonary disease due to these organisms was treated with amikacin for six months and with cotrimoxazole (sulphamethoxazole-trimethoprim) for one year. Only one patient had sustained bacteriological conversion. Three patients showed a transient reduction of bacillary load during the period of amikacin administration. The rest all failed to show response. Thus sulphamethoxazole was found to have no activity against Mycobacterium avium-intracellulare, and amikacin has doubtful activity when used alone in treatment of M. avium-intracellulare infection.
All Author(s) ListYEW WW, TAM CM, CHAN CY, LI MSK, CHENG AFB
Journal nameInternational Journal of Clinical Pharmacology Research
Year1993
Month1
Day1
Volume Number13
Issue Number2
PublisherBIOSCIENCE EDIPRINT INC
Pages65 - 68
ISSN0251-1649
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesPharmacology & Pharmacy

Last updated on 2020-01-04 at 01:21